|
Hunting ELKS for a
10%-Plus Yield
|
|
Published:
August 4, 2008
Citigroup (NYSE: C) is the big name behind
ELKS, an acronym for
"Equity-LinKed Securities." ELKS are structure product based
on an underlying common stock. They have a maturity date
(usually a year from the issue date) and offer either cash or
the underlying shares back at maturity. Typically, ELKS pay
quarterly or semi-annual dividends to investors. One of the ELKS
I particularly like is
Citigroup ELKS 11% Linked to Celgene (AMEX: EHC, $10.60).
Snapshot: These ELKS are based on the common stock
of biotech giant Celgene (Nasdaq: CELG). Citigroup issued 2.96
million shares of EHC in March 2008 at $10 a piece, raising
$29.6 million. The security matures in April 2009, at which
point you will either receive your principal back, or shares of
Celgene.
Dividend and principal payments are secured by Citigroup's
investment-grade rating of "A1" from Moody's and "A" from
Standard & Poor's. The ELKS rank as senior unsecured debt,
and debt holders have a claim on Citigroup's assets before
equity holders in case of insolvency. Although the bank has
been under pressure from bad mortgage loans, it has more
than $2 trillion in assets and is generally considered
well-capitalized.
Dividend: EHC
pays a total dividend of $1.1275, divvied up into two payments
-- one on October 6, 2008 and the second on April 6, 2009. At
today's share price, that equates to a yield of 10.6%. To capture the payments, you'll need to own
the shares before they go ex-dividend, usually five business
days before the payment dates.
The payments consist of $0.8226 a share coming from option
premiums (fees from option sales), which are treated as
short-term capital gains and taxed as regular income. The
balance of $0.3049 is paid as interest, which is also taxable at
your ordinary income tax rate. Thus, the shares are suitable for
a tax-deferred account.
Outlook: The "downside threshold price" for shares
of Celgene is $36.17. That means so long as CELG shares stay
above that price during the next nine months, you'll get back
$10 in cash as principal repayment for every equity-linked
security you own. If you'd prefer to receive Celgene stock, you
can use these ELKS like warrants and opt to get the equivalent
value in shares instead.
In the unlikely event the shares fall to the threshold price or
below, you'll get 0.16589 shares of Celgene for each ELKS. If
Celgene's shares were to go down below the threshold price of
$36.17 and stay there, at maturity you would receive less than
your original principal in equivalent CELG shares. Say Celgene
declined to $36.17 a share. At the 0.16589 exchange rate, you
would receive just $6 worth of Celgene shares for each ELKS
($36.17*0.16589).
The risk of that happening appears low at this time. Selling
today at $73.92, the shares have traded above $40 since early
2006. Over the past year they've defied gravity, gaining more
than +20% while the S&P 500 has lost close to -13%.
Looking ahead, Celgene's future appears bright. It has a
blockbuster blood cancer drug Revlimid and a dynamic pipeline of
psoriasis and cancer drugs that should ensure future growth.
With the
shares trading near their $10 par value, we see little downside
and good upside in EHC.
Since only 2,200 shares change hands daily, interested investors
may want to consider buying small lots over several days, so as
not to move the price.
Good Investing!
Carla Pasternak
Editor
High-Yield
Investing
About High-Yield Investing
High-Yield Investing is
a monthly investment newsletter that brings you a wealth of information on the
market's leading income stocks and funds, as well as a host of relatively
unknown investment options that you probably won't find coverage of anywhere
else. Many
of these securities provide investors with annual dividend yields of 10%, 15%,
even 20% or more. The newsletter not only provides subscribers with
investing ideas that produce incredibly high dividend yields, but the kicker is
that these high-yield investments have also consistently outperformed the major
market averages. (Learn
More)
About Carla Pasternak
Editor of StreetAuthority.com's High-Yield Investing newsletter since its
inception in May 2004, Carla Pasternak draws on a variety of financial
backgrounds to make profitable calls on income-generating stocks for her
readers.
Carla has been employed in the investment industry for more than two decades.
In addition to her work as a writer for several nationally recognized financial
publishers, her previous experience includes a position as president of a
well-respected investor relations firm. She has also been writing shareholder
reports for public companies since 1980.
A highly successful investment analyst, Carla specializes in high-yield,
income-paying stocks. In that pursuit, she's always mindful to select companies
that not only pay rich dividends, but that also deliver strong long-term capital
gains. Furthermore, Carla's experience in writing SEC filings gives her the
added insight required for her to truly understand a company's current and
future financial health.
On the educational front, Carla holds BA, MA, MBA and Ph.D. degrees. When
she's not watching the market, she's teaching business courses at the college
level and managing millions of dollars in portfolio assets.
To learn more about Carla Pasternak's premium income investing newsletter -- High-Yield
Investing -- please visit
this link.
|
|
|
|
|
| FREE
six times a week, our newsletter contains actionable investment ideas from
today's leading market analysts. |
|
|
|
|
The Next 437 Banks That Could Fail
There are 7,830 banks in the United
States -- and 437 are in immediate danger of failing.
If you have cash in any of
these banks your savings could be at
risk.
The Best Stocks to Hold Forever
Few people realize these stocks
even exist.
But many of the richest, most
successful investors, politicians and businessmen have been quietly cashing in
on them for decades
Here's how you can too...
|
|
|
|
|
